CD20 is a cell-surface marker expressed on mature B cells and most malignant B cells, but
not stem or plasma cells. It is an ideal target for monoclonal antibodies (mAb), such as …

CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost
all normal and malignant B cells. It is also the target for rituximab, the most effective anti …

Recent success in cancer immunotherapy has reinvigorated the hypothesis that the immune
system can control many if not most cancers, in some cases producing durable responses in …

Despite the rapid and widespread integration of chimeric CD20 monoclonal antibody (mAb),
rituximab, into the management of non-Hodgkin lymphoma, its efficacy remains variable and …

We have previously defined a panel of fully human CD20 mAb. Most of these were
unexpectedly efficient in their ability to recruit C1q to the surface of CD20-positive cells and …

Despite the clinical success of anti-CD20 monoclonal antibody (mAb) in the treatment of
lymphoma, there remains considerable uncertainty about its mechanism of action. Here we …

Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma,
there remains considerable uncertainty about their mechanism (s) of action. Here, we show …

CD40 is essential in enabling antigen-presenting cells to process and present antigen
effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat …

Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …

A simple and efficient method is described for the production of pure bispecific F (ab'gamma)
2 heterodimers, in which the individual antibody Fab'gamma fragments are joined via a …